Use of paclitaxel in patients with pre-e
✍
Ashwin Gollerkeri; Laurie Harrold; Michal Rose; Diwaker Jain; Barbara Ann Burtne
📂
Article
📅
2001
🏛
John Wiley and Sons
🌐
French
⚖ 47 KB
Cardiac toxicity is frequently the indication for discontinuation of an anthracycline in patients with tumors which remain anthracycline-sensitive. During the 1990s, the most frequently used second-line agents at the Yale Cancer Center (YCC) were the taxanes. The goal of this retrospective analysis